Bicara Therapeutics (BCAX) EPS (Weighted Average and Diluted) (2023 - 2026)
Bicara Therapeutics posted quarterly EPS (Weighted Average and Diluted) of -$0.93 for Q1 2026, down 36.76% year-on-year from -$1.47 in Q1 2025, and down 36.76% on a QoQ basis from -$0.68 in Q4 2025.
Bicara Therapeutics (BCAX) has 4 years of EPS (Weighted Average and Diluted) data on file, last reported at -$0.93 in Q1 2026.
- For the quarter ending Q1 2026, EPS (Weighted Average and Diluted) fell 36.76% year-over-year to -$0.93; the trailing twelve-month figure through Mar 2026 stood at -$2.78 (up 80.24% YoY), and the FY2025 full-year result was -$2.52, up 37.78% from the prior year.
- EPS (Weighted Average and Diluted) for Q1 2026 stood at -$0.93, down from -$0.68 in the prior quarter.
- Across five years, EPS (Weighted Average and Diluted) topped out at $7.22 in Q4 2024 and bottomed at -$38.23 in Q3 2023.
- The 4-year median for EPS (Weighted Average and Diluted) is -$0.93 (2026), against an average of -$8.5.
- The widest annual swing landed in 2024, when EPS (Weighted Average and Diluted) jumped 137.16%; it then sank 109.42% in 2025.
- A 4-year view of EPS (Weighted Average and Diluted) shows it stood at -$19.43 in 2023, then surged by 137.16% to $7.22 in 2024, then tumbled by 109.42% to -$0.68 in 2025, then plunged by 36.76% to -$0.93 in 2026.
- The last three EPS (Weighted Average and Diluted) figures came in at -$0.93 (Q1 2026), -$0.68 (Q4 2025), and -$0.67 (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EPS (Weighted Avg. Diluted) (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | -4.43 |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 3,086.42 |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | 0.00 |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 4.02 |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 6.75 |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 1.51 |
| 10 | Bicara Therapeutics | 1.25 Bn | 1.25 Bn | - | -0.93 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -0.93 |
| Dec 31, 2025 | -0.68 |
| Sep 30, 2025 | -0.67 |
| Jun 30, 2025 | -0.50 |
| Mar 31, 2025 | -0.68 |
| Dec 31, 2024 | 7.22 |
| Sep 30, 2024 | -1.60 |
| Jun 30, 2024 | -19.01 |
| Mar 31, 2024 | -18.94 |
| Dec 31, 2023 | -19.43 |
| Sep 30, 2023 | -38.23 |